Patent intelligence · US
US 8449909
Abuse-deterrent drug formulations
Abuse-deterrent drug formulations
Patent details — US 8449909
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 28, 2013
- Expiration
- May 23, 2033
- Applicant
- Collegium Pharmaceutical, Inc.
- Claims
- 26
- CPC classes
- A61K, A61K31/13, A61K31/135, A61K31/20
Quick answer
US 8449909 (Abuse-deterrent drug formulations) is held by Collegium Pharmaceutical, Inc.. Status: granted. Granted May 28, 2013. Expires May 23, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Collegium Pharmaceutical, Inc.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K31/13, A61K31/135, A61K31/20, A61K31/4458, A61K31/485
More from Collegium Pharmaceutical, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11191758
Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors
granted -
US 10668060
Tamper-resistant pharmaceutical compositions of opioids and other drugs
granted -
US 10646485
Process of making stable abuse-deterrent oral formulations
granted -
US 10525052
Abuse-deterrent drug formulations
granted -
US 10525053
Abuse-deterrent pharmaceutical compositions of opioids and other drugs
granted -
US 10188644
Process of making stable abuse-deterrent oral formulations
granted -
US 10004729
Tamper-resistant pharmaceutical compositions of opioids and other drugs
granted -
US 9968598
Process of making stable abuse-deterrent oral formulations
granted
Frequently asked questions
What is US patent 8449909?
US 8449909 (Abuse-deterrent drug formulations) is held by Collegium Pharmaceutical, Inc.. Status: granted. Granted May 28, 2013. Expires May 23, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8449909?
Collegium Pharmaceutical, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 28 pharmaceutical patents for this assignee.
When does US 8449909 expire?
Our index shows an expiration date of May 23, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.